tadalafil has been researched along with natriuretic peptide, brain in 10 studies
| Studies (tadalafil) | Trials (tadalafil) | Recent Studies (post-2010) (tadalafil) | Studies (natriuretic peptide, brain) | Trials (natriuretic peptide, brain) | Recent Studies (post-2010) (natriuretic peptide, brain) |
|---|---|---|---|---|---|
| 1,742 | 392 | 1,089 | 16,317 | 1,867 | 8,887 |
| Protein | Taxonomy | tadalafil (IC50) | natriuretic peptide, brain (IC50) |
|---|---|---|---|
| Atrial natriuretic peptide receptor 1 | Homo sapiens (human) | 0.006 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 3 (30.00) | 2.80 |
| Authors | Studies |
|---|---|
| Doran, AK; Hill, W; Shapiro, S; Traiger, G; Zhang, L | 1 |
| Barbaro, NR; Calhoun, D; Coelho, OR; de Faria, AP; Ferreira-Melo, SE; Fontana, V; Matos-Souza, JR; Modolo, R; Moreno, H; Santos, RC; Yugar-Toledo, JC | 1 |
| Behr, J; Geiseler, J; Huppmann, P; Ihle, F; Leuchte, HH; Meis, T; Neurohr, C; Tufman, A; von Wulffen, W; Zimmermann, GS | 1 |
| Barberà, JA; Blair, C; Frost, AE; Galiè, N; Ghofrani, HA; Gillies, H; Grünig, E; Harris, JH; Hoeper, MM; Langley, J; McLaughlin, VV; Miller, KL; Oudiz, RJ; Peacock, AJ; Rubin, LJ; Simonneau, G; Vachiery, JL; Vonk-Noordegraaf, A; White, RJ | 1 |
| Chin, K; Corona-Villalobos, CP; Damico, R; Gashouta, MA; Girgis, RE; Hassoun, PM; Housten, T; Hulme, OL; Khair, R; Kolb, TM; Lechtzin, N; Mathai, SC; Minai, OA; Pisanello, C; Pullins, EH; Sato, T; Tedford, RJ; Torres, F; Zamanian, RT; Zimmerman, SL | 1 |
| Baines, CP; Burnett, JC; Chakir, K; Cruz Rivera, N; Domeier, TL; Dozier, DG; Emter, CA; Ferguson, BS; Gutiérrez-Aguilar, M; Heublein, DM; Hiemstra, JA; Ivey, JR; Krenz, M; Lee, DI; Marshall, KD; McDonald, KS; Minervini, G; Scherf, C; Zgoda, PJ | 1 |
| Cheong, FY; Farber, HW; Gower, AC | 1 |
| Argiento, P; Badagliacca, R; D'Alto, M; Farro, A; Golino, P; Naeije, R; Papa, S; Romeo, E; Russo, MG; Sarubbi, B; Vizza, CD | 1 |
| Burnett, JC; Chen, HH; Hodge, DO; McKie, PM; Slusser, JP; Wan, SH | 1 |
| Adel, FW; Benike, SL; Burnett, JC; Chen, HH; Hubers, SA; Scott, C; Wan, SH | 1 |
4 trial(s) available for tadalafil and natriuretic peptide, brain
| Article | Year |
|---|---|
Tadalafil-induced improvement in left ventricular diastolic function in resistant hypertension.
Topics: Aged; Blood Pressure; Carbolines; Cross-Over Studies; Cyclic GMP; Diastole; Drug Resistance; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; Middle Aged; Natriuretic Peptide, Brain; Nitrites; Phosphodiesterase 5 Inhibitors; Single-Blind Method; Tadalafil; Ventricular Dysfunction, Left; Ventricular Function, Left | 2014 |
Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.
Topics: Adult; Aged; Carbolines; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Hospitalization; Humans; Hypertension, Pulmonary; Kaplan-Meier Estimate; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Phenylpropionates; Pyridazines; Risk Factors; Tadalafil | 2015 |
Effects of phosphodiesterase V inhibition alone and in combination with BNP on cardiovascular and renal response to volume load in human preclinical diastolic dysfunction.
Topics: Aged; Aged, 80 and over; Cyclic GMP; Drug Combinations; Female; Glomerular Filtration Rate; Heart Failure, Diastolic; Humans; Male; Myocardial Contraction; Natriuretic Peptide, Brain; Phosphodiesterase 5 Inhibitors; Renal Elimination; Tadalafil | 2021 |
Cardiorenal Effects of Long-Term Phosphodiesterase V Inhibition in Pre-Heart Failure.
Topics: Animals; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Glomerular Filtration Rate; Heart Failure; Humans; Natriuretic Peptide, Brain; Sodium; Tadalafil | 2022 |
6 other study(ies) available for tadalafil and natriuretic peptide, brain
| Article | Year |
|---|---|
Safety, tolerability, and efficacy of overnight switching from sildenafil to tadalafil in patients with pulmonary arterial hypertension.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carbolines; Endothelin Receptor Antagonists; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Natriuretic Peptide, Brain; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Retrospective Studies; Sildenafil Citrate; Sulfones; Tadalafil | 2013 |
Haemodynamic changes in pulmonary hypertension in patients with interstitial lung disease treated with PDE-5 inhibitors.
Topics: Aged; Aged, 80 and over; Carbolines; Female; Follow-Up Studies; Hemodynamics; Humans; Hypertension, Pulmonary; Lung Diseases, Interstitial; Male; Middle Aged; Natriuretic Peptide, Brain; Phosphodiesterase 5 Inhibitors; Pilot Projects; Piperazines; Purines; Respiratory Function Tests; Sildenafil Citrate; Sulfonamides; Tadalafil; Walking | 2014 |
Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension.
Topics: Drug Therapy, Combination; Female; Heart Ventricles; Humans; Hypertension, Pulmonary; Magnetic Resonance Imaging; Male; Middle Aged; Natriuretic Peptide, Brain; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Prospective Studies; Pyridazines; Scleroderma, Systemic; Stroke Volume; Tadalafil; Ultrasonography; Vascular Resistance | 2015 |
Saxagliptin and Tadalafil Differentially Alter Cyclic Guanosine Monophosphate (cGMP) Signaling and Left Ventricular Function in Aortic-Banded Mini-Swine.
Topics: Adamantane; Animals; Atrial Natriuretic Factor; Cyclic GMP; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Echocardiography; Hypertrophy, Left Ventricular; Male; Natriuretic Peptide, Brain; Neuropeptide Y; Phosphodiesterase 5 Inhibitors; Signal Transduction; Swine; Swine, Miniature; Tadalafil; Ventricular Function, Left | 2016 |
Changes in gene expression profiles in patients with pulmonary arterial hypertension associated with scleroderma treated with tadalafil.
Topics: Aged; Down-Regulation; Extracellular Matrix; Female; Golgi Apparatus; Humans; Hypertension, Pulmonary; Immunity, Innate; Interleukin-12; Male; Microarray Analysis; Middle Aged; Natriuretic Peptide, Brain; Phosphodiesterase 5 Inhibitors; Pilot Projects; Potassium Channels, Voltage-Gated; Scleroderma, Systemic; Signal Transduction; Tadalafil; Transcriptome; Treatment Outcome; Up-Regulation; Walk Test | 2017 |
Risk Reduction and Right Heart Reverse Remodeling by Upfront Triple Combination Therapy in Pulmonary Arterial Hypertension.
Topics: Adult; Antihypertensive Agents; Atrial Remodeling; Cardiac Catheterization; Drug Therapy, Combination; Echocardiography; Epoprostenol; Female; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Phenylpropionates; Pulmonary Arterial Hypertension; Pyridazines; Retrospective Studies; Risk Reduction Behavior; Tadalafil; Treatment Outcome; Vascular Resistance; Vasodilator Agents; Ventricular Function, Right; Ventricular Remodeling; Walk Test | 2020 |